You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
冠昊生物(300238.SZ):上半年淨利升213.72%至2696.69萬元
格隆匯 07-20 19:24

格隆匯 7 月 20日丨冠昊生物(300238.SZ)披露2020年半年度報告,實現營業收入2.04億元,同比下降1.96%;歸屬於上市公司股東的淨利潤2696.69萬元,同比增長213.72%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤1962.87萬元,上年同期虧損302.99萬元;基本每股收益0.10元。

影響公司損益的主要因素如下:

1.報告期內,公司積極進行生物材料板塊和眼科板塊營銷渠道優化和市場推廣,加速藥業板塊營銷渠道建設,公司生物材料板塊銷售收入基本持平,藥業板塊新藥本維莫德實現銷售收入2698.94萬元;人工晶體產品受疫情影響較大,銷售收入同比下降36.47%,一定程度上影響了公司淨利潤。

2.報告期內,隨着公司新藥產品本維莫德乳膏銷售收入增長,本報告期藥業板塊基本實現盈虧平衡。

3.報告期內,受疫情影響,公司各板塊銷售活動投入均減少,銷售費用明顯下降;管理層為積極應對疫情,降本增效,管理費用明顯下降。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account